drugset / Trial / NCT00568685

Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00568685

Phase 3 Completed 153 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to provide information regarding the relative effectiveness of three different atomoxetine doses in the treatment of Korean children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD)

Timeline

Start
2007-11
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atomoxetine Other / unclassified 0.2 mg/kg Oral
Comparator Atomoxetine Other / unclassified 0.5 mg/kg Oral
Comparator Atomoxetine Other / unclassified 1.2 mg/kg Oral